RBC Capital Mkts initiated coverage on NewAmsterdam Pharma with a new price target

10/30/23 7:23:32 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

RBC Capital Mkts initiated coverage of NewAmsterdam Pharma with a rating of Outperform and set a new price target of $25.00

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$NAMS

Date	Price Target	Rating	Analyst
6/17/2025	$42.00	Buy	Citigroup
6/10/2025	$44.00	Buy	Stifel
6/4/2025	$42.00	Overweight	Cantor Fitzgerald
12/30/2024	$48.00	Buy	H.C. Wainwright
5/15/2024		Buy	TD Cowen
3/14/2024	$35.00	Sector Outperform	Scotiabank
1/18/2024	$30.00	Buy	Guggenheim
1/16/2024	$37.00	Overweight	Piper Sandler